Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. MDxHealth SA
  6. News
  7. Summary
    MDXH   BE0003844611

MDXHEALTH SA

(MDXH)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-09-30 am EDT
0.6770 EUR   -0.73%
08/29Oppenheimer Adjusts MDxHealth Price Target to $21 From $18, Maintains Outperform Rating
MT
08/26BTIG Adjusts Price Target on MDxHealth to $15 From $13, Reiterates Buy Rating
MT
08/26MDXHEALTH SA : Half-year report
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about MDXHEALTH SA
08/29Oppenheimer Adjusts MDxHealth Price Target to $21 From $18, Maintains Outperform Rating
MT
08/26BTIG Adjusts Price Target on MDxHealth to $15 From $13, Reiterates Buy Rating
MT
08/26MDXHEALTH SA : Half-year report
CO
08/25MDxHealth SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/25MDxHealth Reports Half Year 2022 Results
GL
08/25MDxHealth Reports Half Year 2022 Results
AQ
08/25MDXHEALTH SA : 1st-half-year results
CO
08/19Mdxhealth's New Share Capital Amount and New Number of Shares
GL
08/19Mdxhealth's New Share Capital Amount and New Number of Shares
AQ
08/19MDXHEALTH SA : Threshold crossings
CO
08/03MDxHealth Agrees to Buy Exact Sciences' Prostate Cancer Unit for Up to $100 Million
MT
08/03Belgium's MDxHealth To Buy Exact Sciences' Prostrate Cancer Test For $100 Million
MT
08/02Mdxhealth : Acquires Oncotype DX« GPS Prostate Cancer Business from Exact Sciences and Rep..
PU
08/02Transcript : MDxHealth SA, Q2 2022 Earnings Call, Aug 02, 2022
CI
08/02Mdxhealth Acquires Oncotype DX«áGPS Prostate Cancer Business from Exact Sciences and R..
GL
More most relevant news
All news about MDXHEALTH SA
08/29Oppenheimer Adjusts MDxHealth Price Target to $21 From $18, Maintains Outperform Rating
MT
08/26BTIG Adjusts Price Target on MDxHealth to $15 From $13, Reiterates Buy Rating
MT
08/26MDXHEALTH SA : Half-year report
CO
08/25MDxHealth SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/25MDxHealth Reports Half Year 2022 Results
GL
08/25MDxHealth Reports Half Year 2022 Results
AQ
08/25MDXHEALTH SA : 1st-half-year results
CO
08/19Mdxhealth's New Share Capital Amount and New Number of Shares
GL
08/19Mdxhealth's New Share Capital Amount and New Number of Shares
AQ
08/19MDXHEALTH SA : Threshold crossings
CO
More news
News in other languages on MDXHEALTH SA
09/27Brussel hoger van start
09/20Bel20 licht omlaag
09/09Brussel verder omhoog
08/26Rood slot in Brussel
08/26Brussel verder in het rood
08/26VGP trekt Bel20 in het rood
08/26Jerome, un discours ! Jerome, un discours !
08/26EN DIRECT DES MARCHES : TotalEnergies, EDF, Eiffage, Merck, Gap, M..
08/25MDxHealth boekt meer omzet
08/25MDxHealth SA annonce ses résultats pour le semestre clos le 30 juin 2022
More news
Analyst Recommendations on MDXHEALTH SA
08/29Oppenheimer Adjusts MDxHealth Price Target to $21 From $18, Maintains Outperform Rating
MT
08/26BTIG Adjusts Price Target on MDxHealth to $15 From $13, Reiterates Buy Rating
MT
2021Oppenheimer Initiates Coverage on MDxHealth With Outperform Rating, $18 Price Target
MT
2021BTIG Starts MDxHealth SA at Buy With $15 Price Target
MT
2021Piper Sandler Starts MDxHealth SA at Overweight With $15 Price Target
MT
More recommendations
Press releases
08/25MDxHealth Reports Half Year 2022 Results
GL
08/25MDxHealth Reports Half Year 2022 Results
AQ
08/19Mdxhealth's New Share Capital Amount and New Number of Shares
GL
08/19Mdxhealth's New Share Capital Amount and New Number of Shares
AQ
08/02Mdxhealth : Acquires Oncotype DX« GPS Prostate Cancer Business from Exact Sciences and Rep..
PU
More press releases
Upcoming event on MDXHEALTH SA